Description: Orthocell Limited is a regenerative medicine company. The Company is engaged in the development and commercialization of cell therapies and related technologies. The Company's products include CelGro, a collagen medical device for soft tissue repair in use as an augment to rotator cuff repair, guided bone regeneration and repair of articular cartilage, and Autologous Tenocyte Implantation (Ortho-ATI) for chronic, treatment resistant tendon regeneration. CelGro is targeted on a range of orthopedic, reconstructive and surgical applications. Ortho-ATI is a treatment that uses a minimally invasive, non-surgical approach that uses each patient's own tendon derived stem cells to stimulate tendon regeneration and is delivered through ultrasound guided injection under local anesthetic. The Company's Autologous Chondrocyte Implantation (Ortho-ACI) offers treatment for symptomatic defects of the articulating cartilage of the joints, including the knee and ankle.
Home Page: orthocell.com
OCC Technical Analysis
Building 191
Murdoch,
WA
6150
Australia
Phone:
61 8 9360 2888
Officers
| Name | Title |
|---|---|
| Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D. | Exec. Chairman |
| Mr. Paul Frederick Anderson | CEO, MD & Exec. Director |
| Ms. Leslie Wise J.D. | Exec. Director |
| Ms. Nicole Jane Telford | Chief Financial Officer |
| Mr. Alex McHenry | Chief Operating Officer |
| Prof. Ming Hao Zheng | Chief Scientific Officer and Member of Medical & Scientific Advisory Board |
| Mr. Simon Lee Robertson B.Bus, C.A., CA, M Appl. Fin. | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.6609 |
| Price-to-Sales TTM: | 52.1422 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |